Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 1. YM155 suppresses survivin expression in human RD cells. Survivin expression decreased after 24 h of treatment with 2-50 nM of YM155 in a dose- dependent manner. (A) Survivin mRNA expression was measured by quantative real-time PCR. YM155 doses of 5 nM and greater suppress survivin mRNA compared to YM155 negative control (*P<0.005, **P<0.001). (B) YM155 suppresses survivin protein in human RD cells as well as siRNA of survivin (C).

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Negative Control

Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 2. YM155 inhibits RD cell line growth at 24 h (A) and 48 h (B) incuba- tion in a dose-dependent manner (*P<0.001, **P<0.0001).

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques:

Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 4. YM155 inhibits RD cell line growth in combination with 10 µM cisplatin at 24 h (A) and 48 h (B) incubation (*P<0.05, **P<0.0001).

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques: Incubation

Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 5. Flow cytometry using Annexin V and propidium iodide (PI). Apoptotic cells were defined as Annexin V-positive and PI-negative (Q4). The combination of YM155 and cisplatin (D) resulted in higher apoptosis than control (A) and either treatment alone (B and C).

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques: Flow Cytometry, Control

Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 6. Relative caspase-3 activity following combined treatment with YM155 and cisplatin was greater than with either treatment alone.

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques: Activity Assay

Journal: International journal of oncology

Article Title: Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.

doi: 10.3892/ijo.2016.3438

Figure Lengend Snippet: Figure 7. Nude mice (BALB/c nu/nu) subcutaneously injected with RD cells formed palpable tumors. Tumor volume was measured as described in Materials and methods, and the mean tumor volume over the 28-day experimental period was used to generate the graph. The growth rate was calculated during the treatment period. The combination of YM155 and cis- platin resulted in the greatest inhibition of tumor growth (*P<0.0001).

Article Snippet: YM155 was purchased from Selleck Chemicals (Houston, TX, USA) and dissolved with DMSA to a final stock solution concentration of 1 mM cisplatin (Wako Pure Chemical industries, Osaka, Japan) was dissolved in sterile water to a final stock solution concentration of 1 mM.

Techniques: Injection, Inhibition

Journal: Molecular medicine reports

Article Title: Survivin activates NF‑κB p65 via the IKKβ promoter in esophageal squamous cell carcinoma.

doi: 10.3892/mmr.2015.4737

Figure Lengend Snippet: Figure 2. YM155 inhibited the expression of survivin, NF‑κB p65, IKKα and IΚΚβ in Eca109 and KYSE150 cells. (A) Eca109 and KYSE150 cells were incubated with 0.005, 0.05, 0.5, 5 and 50 µM YM155 for 48 h. Cells incubated with the culture medium served as the control group. Experiments were performed in triplicate. Eca109 and KYSE150 cells were treated with 0 (blank), 0.05, 0.5, and 5.0 µM YM155. The expression of survivin, NF‑κB p65, IΚΚβ and IΚΚα were analyzed by (B and C) western blotting and (D and E) RT‑qPCR. Western blotting of survivin, p‑NF‑κB p65, NF‑κB p65, IΚΚβ and IΚΚα proteins was conducted using total protein isolated from cells, with GADPH serving as a loading control. Transcript levels were measured by RT‑qPCR of total isolated RNA, with GADPH serving as an internal control. YM155 inhibited expression of survivin and NF‑κB p65, IKKα and IΚΚβ in (B and D) Eca109 and (C and E) KYSE150 cells. Columns demonstrate the mean values from triplicate experiments and the error bars indicate standard deviation. *P<0.05; **P<0.01 vs. control. RT‑qPCR, quantitative reverse transcription‑polymerase chain reaction; NF‑κB p65, transcription factor p65; IKKα, inhibitor of nuclear factor κB kinase subunit α; IΚΚβ, inhibitor of nuclear factor κB kinase subunit β; p, phosphorylated; mRNA, messenger RNA.

Article Snippet: After 24 h, cells were exposed to survivin inhibitor, YM155 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at various concentrations (0, 0.005, 0.05, 0.5, 5 and 50 μM) for 48 h. Following incubation at 37 ̊C, 0.4% Trypan Blue solution (Sigma‐Aldrich, St. Louis, MO, USA) was added to each well.

Techniques: Expressing, Incubation, Control, Western Blot, Isolation, Standard Deviation, Reverse Transcription Polymerase Chain Reaction

Journal: Developmental cell

Article Title: Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity

doi: 10.1016/j.devcel.2019.03.011

Figure Lengend Snippet: KEY RESOURCE TABLE

Article Snippet: YM155 , Tocris , 6491.

Techniques: Virus, Recombinant, Multiplex sample analysis, Isolation, Luciferase, Cloning, Reverse Transcription, Activity Assay, Control, shRNA, Sequencing, Plasmid Preparation, Software, SYBR Green Assay, Transfection

Journal: Cancers

Article Title: Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs

doi: 10.3390/cancers11101550

Figure Lengend Snippet: Spironolactone decreases survivin expression and survivin reductions imitate the chemosensitizing effects of spironolactone. Cells treated with or without 25 µM spironolactone (SPL) for three days were subjected to an immunoblot analysis for survivin expression ( a , b ). YM155, a pharmacological survivin inhibitor, at the concentration of 10 nM and the knockdown of survivin reduced survivin expression in cancer cells (A549) ( c ). The pharmacological or genetic inhibition of survivin sensitized cancer cells (A549) to chemotherapeutic reagents (GEM, gemcitabine, 0.1 µM; OSI, osimertinib, 2 µM) ( d ). * p < 0.05.

Article Snippet: Osimertinib and YM155 were purchased from Chemscene LLC. (Monmouth Junction, NJ, USA) and dissolved in DMSO to 10 mM and 20 μM, respectively, as stock solutions.

Techniques: Expressing, Western Blot, Concentration Assay, Knockdown, Inhibition